<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01879878</url>
  </required_header>
  <id_info>
    <org_study_id>POUDER</org_study_id>
    <secondary_id>U1111-1144-2013</secondary_id>
    <nct_id>NCT01879878</nct_id>
  </id_info>
  <brief_title>Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]</brief_title>
  <acronym>POUDER</acronym>
  <official_title>Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the POUDER trial is to determine the feasibility of a randomized controlled trial
      regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin
      in patients with advanced pancreatic ductal adenocarcinoma that receive palliative
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly classified into two groups - verum and placebo. The patients in the
      experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg
      sulforaphane active substance per day over one year as nutrition supplement whereas patients
      assigned to the placebo group will receive inactive substance (methylcellulose) with
      identical capsule and portion distribution.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of a randomized controlled trial</measure>
    <time_frame>One year</time_frame>
    <description>Main objective is to test the feasibility of a randomized controlled trial regarding the application of freeze-dried broccoli sprouts rich in sulforaphane and quercetin in patients with advanced, surgically non-resectable pancreatic ductal adenocarcinoma treated with palliative chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease status (imaging and tumor markers)</measure>
    <time_frame>One year</time_frame>
    <description>Disease status (cancer progress or regress): CT-imaging staging (if available) and serum tumor markers (CEA and CA-19-9) peaks as additional parameters that provide insight into disease status.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Substance bioavailability</measure>
    <time_frame>One year</time_frame>
    <description>Urine analysis as marker of substance systemic bioavailability (conversion of the precursor glucoraphanin to the active drug substance sulforaphane). Urine analysis serves as control of the regular intake of the test substance as well.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Verum, broccoli sprout grain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active sulforaphane distributed in capsules each containing broccoli sprout grain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive substances (methylcellulose) with identical capsule and portion distribution</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Verum, broccoli sprout grain</intervention_name>
    <description>Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.</description>
    <arm_group_label>Verum, broccoli sprout grain</arm_group_label>
    <other_name>glucoraphanin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced, surgically non-treatable pancreatic ductal adenocarcinoma (surgical
             exploration, intraoperative biopsy but also palliative bypass interventions
             (bileodigestive anastomosis and/or gastroenterostomy because of preoperative
             cholestasis or impaired gastric emptying due to tumor-mass effect)

          -  Intact gastric emptying

          -  Written informed consent

          -  Patients â‰¥18 years of age

          -  Palliative chemotherapy

        Exclusion Criteria:

          -  Intolerance to broccoli or its ingredients

          -  Impaired mental status or language problems / barriers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Schemmer, Prof. Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Herr, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Schemmer, Prof. Dr. med.</last_name>
    <phone>+49 6221 566205</phone>
    <email>peter.schemmer@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vladimir J. Lozanovski, M.D.</last_name>
    <phone>+49 6221 5636439</phone>
    <email>vladimir.lozanovski@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of General and Transplant Surgery, University Hospital of Heidelberg, Germany</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir J. Lozanovski, M.D.</last_name>
      <phone>+49 6221 5636439</phone>
      <email>vladimir.lozanovski@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Vladimir J. Lozanovski, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2013</study_first_submitted>
  <study_first_submitted_qc>June 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2013</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Peter Schemmer</investigator_full_name>
    <investigator_title>Prof. Dr. med. Peter Schemmer, MBA</investigator_title>
  </responsible_party>
  <keyword>pancreatic adenocarcinoma</keyword>
  <keyword>broccoli sprouts</keyword>
  <keyword>sulforaphane</keyword>
  <keyword>palliative chemotherapy</keyword>
  <keyword>cancer stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulforafan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

